[Body plethysmographic investigations with the new bronchodilator NAB365 (author's transl)].
NAB 365, a new beta2-adrenergic bronchodilator was tested in oral doses of 0,01, 0,02, 0,03, and 0,04 mg. An acute trial was carried out in outpatients, suffering from chronic obstructive airways disease. with doses of 0,02 and 0,04 mg NAB 365 a quick, dose related and statistically significant bronchodilation without remarkable side effects was found.
D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D010627:Phenethylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010993:Plethysmography, Whole Body
D001993:Bronchodilator Agents; D010627:Phenethylamines
Bodyplethysmographische Untersuchungen mit dem neuen Bronchospasmolytikum NAB 365